Actinogen Medical Limited (FRA:3AC)

Germany flag Germany · Delayed Price · Currency is EUR
0.0295
+0.0005 (1.72%)
Last updated: Dec 5, 2025, 8:03 AM CET
78.79%
Market Cap 102.97M
Revenue (ttm) 3.06M
Net Income (ttm) -8.22M
Shares Out n/a
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 12,350
Open 0.0295
Previous Close 0.0290
Day's Range 0.0295 - 0.0295
52-Week Range 0.0080 - 0.0365
Beta n/a
RSI 54.66
Earnings Date Nov 24, 2025

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 6
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3AC
Full Company Profile

Financial Performance

In 2025, Actinogen Medical's revenue was 5.49 million, a decrease of -44.73% compared to the previous year's 9.93 million. Losses were -14.73 million, 12.9% more than in 2024.

Financial numbers in AUD Financial Statements

News

There is no news available yet.